Advancing Diagnostic Solutions for Myeloid Malignancies
Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells. Myeloid malignant diseases comprise and acute (acute myeloid leukemia) stages.
Invivoscribe is dedicated to advancing diagnostic solutions for the characterization and treatment of myeloid malignancies. These malignancies include both chronic conditions like myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML), and acute stages such as acute myeloid leukemia (AML).
Download Invivoscribe’s Hematological Testing Menu
Comprehensive Solutions for AML & Related Neoplasms
Acute myeloid leukemia (AML) and related neoplasms are aggressive disorders characterized by the rapid proliferation of abnormal myeloid cells. Early and accurate diagnosis is crucial for improving patient outcomes. Our diagnostic products and services are designed to help physicians make more informed treatment decisions through precise, reliable testing.
FLT3 Testing for Personalized Treatment Plans
Mutations in the FLT3 gene are commonly found in AML patients and are associated with a higher risk of relapse and poor prognosis. Invivoscribe offers a range of globally standardized FLT3 testing solutions that provide essential data, enabling clinicians to tailor treatment plans and monitor therapy response effectively.
IVDR Approved LeukoStrat® CDx FLT3 Mutation Assay
Now available in regions where CE 2797 IVD approved products are sold. The LeukoStrat® CDx FLT3 Mutation Assay is a globally standardized, PCR-based in vitro diagnostic test used to detect FLT3 mutations in AML patients. This test plays a critical role in making treatment decisions by identifying prognostic mutations that are also clinically actionable.
We are also excited to offer the FLT3 ITD MRD Assay & Software and the NPM1 MRD Assay & Software, providing clinicians with the tools needed for enhanced disease monitoring:
No baseline sample required
FLT3 ITD MRD Assay detects and reports insertions ranging from 9 to 252 base pairs
NPM1 MRD Assay detects and report mutations A, B, D, or ‘Other’
Dockerized software is portable, automatable, and easily integrated into downstream reporting systems and/or LIMS
Direct contact technical support
Find products for your research
